Publication: Pharmacokinetics of Quinine, Chloroquine and Amodiaquine: Clinical Implications
Issued Date
1996-01-01
Resource Type
ISSN
03125963
Other identifier(s)
2-s2.0-0030007219
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Clinical Pharmacokinetics. Vol.30, No.4 (1996), 263-299
Suggested Citation
Sanjeev Krishna, Nicholas J. White Pharmacokinetics of Quinine, Chloroquine and Amodiaquine: Clinical Implications. Clinical Pharmacokinetics. Vol.30, No.4 (1996), 263-299. doi:10.2165/00003088-199630040-00002 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/17822
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Pharmacokinetics of Quinine, Chloroquine and Amodiaquine: Clinical Implications
Author(s)
Other Contributor(s)
Abstract
Malaria is associated with a reduction in the systemic clearance and apparent volume of distribution of the cinchona alkaloids; this reduction is proportional to the disease severity. There is increased plasma protein binding, predominantly to α1-acid glycoprotein, and elimination half-lives (in healthy adults quinine t1/2z= 11 hours, quinidine t1/2z= 8 hours) are prolonged by 50%. Systemic clearance is predominantly by hepatic biotransformation to more polar metabolites (quinine 80%, quinidine 65%) and the remaining drug is eliminated unchanged by the kidney. Quinine is well absorbed by mouth or following intramuscular injection even in severe cases of malaria (estimated bioavailability more than 85%). Quinine and chloroquine may cause potentially lethal hypotension if given by intravenous injection. Chloroquine is extensively distributed with an enormous total apparent volume of distribution (Vd) more than 100 L/kg, and a terminal elimination half-life of 1 to 2 months. As a consequence, distribution rather than elimination processes determine the blood concentration profile of chloroquine in patients with acute malaria. Parenteral chloroquine should be given either by continuous intravenous infusion, or by frequent intramuscular or subcutaneous injections of relatively small doses. Oral bioavailability exceeds 75%. Amodiaquine is a pro-drug for the active antimalarial metabolite desethylamodiaquine. Its pharmacokinetic properties are similar to these of chloroquine although the Vd is smaller (17 to 34 L/kg) and the terminal elimination half-life is 1 to 3 weeks.